Researchers from a southeastern Spanish university announced the discovery of a molecule that could be used as a potential drug to fight the effects of a Zika virus infection.
In a statement on Saturday, the San Antonio Catholic University of Murcia (UCAM) said that scientists belonging to its prestigious Bioinformatics and High-Performance Computing research group had found that a compound previously used as an antibiotic countered the symptoms of the mosquito-borne disease, Efe news reported.
"It's a drug that had been withdrawn from the market because it had lost its potency as an antibiotic, but we know it can be administered to humans," said Jos� Pedro Cer�n, a member of the research team.
The molecular structure of the proteins involved in the Zika virus' replication process was first described only a year ago.
Researchers focused on an antibiotic that had been previously prescribed to fend off "nosocomial" infections (those acquired inside a hospital).
The teams of both universities have now patented the molecule as an anti-Zika treatment.
The compound, known as "novobiocin," had phenomenal results when given to mice: a 100 per cent cure rate.
The only pending task is to figure out the exact dose needed for humans to achieve the same successful outcome.
The Zika virus—named after a forest in Uganda where it was first isolated in 1947—saw a swift expansion between early 2015 and January 2016 throughout South America and the Caribbean, when factors such as tropical climates and insufficient mosquito-population control led the World Health Organization to term it an epidemic and global emergency
